Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Scopus BioPharma Sends Letter Urging Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card
Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster’s Campaign Against the Company
